复方夏天无与双氯芬酸钠治疗膝骨关节炎临床对照研究.docVIP

复方夏天无与双氯芬酸钠治疗膝骨关节炎临床对照研究.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
复方夏天无与双氯芬酸钠治疗膝骨关节炎临床对照研究

复方夏天无与双氯芬酸钠治疗膝骨关节炎临床对照研究   [摘要]为探讨复方夏天无治疗膝骨关节炎(OA)患者的疗效和安全性,本院门诊及住院部将符合纳入标准的79例膝OA患者,随机分为试验组和对照组。试验组(n=41例)服用复方夏天无1.8 g?dlt;supgt;-1lt;/supgt;,对照组(n=38例)服用双氯芬酸钠75 mg?dlt;supgt;-1lt;/supgt;。通过12周的治疗,患者、医生疗效评价总有效率在试验组是68.29%,63.41%,在对照组是71.05%,63.16%,2组比较无显著性差异。试验组和对照组在主要疗效指标(20 m步行痛)和次要疗效指标(关节触痛、WOMAC骨关节炎指数和健康状况调查问卷SF-36)均较治疗前明显改善(Plt;0.05),但2组疗效比较无显著性差异。与药物相关的不良事件发生率在试验组为24.39%,明显低于对照组47.37%,组间比较有显著性差异(Plt;0.05)。对照研究发现,应用复方夏天无治疗膝OA疗效与双氯芬酸钠基本相当,但耐受性更好,具有良好的临床应用前景。   [关键词]复方夏天无;双氯芬酸;骨关节炎;疗效;安全性   [收稿日期]2014-04-29   [通信作者]*谢其冰,博士,副教授,主要从事风湿免疫性疾病基础和临床研究,Tel:E-mail: xieqibing1971@163.com   Controlled clinical study on compound Decumbent Corydalis Rhizome   and diclofenac in treatment of knee osteoarthritis   ZUO Chuan, YIN Geng, CEN Xiao-min, XIE Qi-bing*   (Department of Clinical Immunology, West China Hospital, Sichuan University, Chengdu 610041, China)   [Abstract]To evaluate the efficacy and safety of compound Decumbent Corydalis Rhizome (DCR) in treating patients with knee osteoarthritis (OA). Totally 79 patients with knee osteoarthritis were selected from out-patient and inpatient departments of West China Hospital and randomly divided into the test group and the control group. The test group(n=41) was given Compound DCR with the dosage of 1.8 g?dlt;supgt;-1lt;/supgt;, while the control group(n=38) was administered with diclofenac sodium with the dosage of 75 mg?dlt;supgt;-1lt;/supgt;. After 12 weeks of treatment, the total efficacy rates based on patients/physicians evaluation for experimental and control groups were 68.29%, 63.41% and 71.05%, 63.16%, respectively, without significant difference between the two groups. Both of the two groups showed significant improvements in the main efficacy indexes (pain on walking 20 m) and minor indexes(tenderness on palpation, Western Ontario and McMaster Universities OA index (WOMAC) and Short-Form Health Survey (SF-36)), but without significant difference in efficacy between them. The incidence of re

文档评论(0)

3471161553 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档